Zymeworks Q1 Revenue of $105.4M Beats Expectations
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 2 days ago
0mins
Should l Buy ARQT?
Reports Q1 revenue $105.4M, consensus $103.66M. "Strong product revenue in the first quarter was driven by continued robust demand for ZORYVE, which remains the leading prescribed branded topical across its three approved indications. During the quarter, we also advanced our pipeline with the initiation of a Phase 1 trial for ARQ-234, our biologic candidate for atopic dermatitis, submission of an sNDA to the FDA to expand the ZORYVE cream indication in atopic dermatitis to patients as young as 3 months, and progress on our Phase 2 proof-of-concept studies of ZORYVE in potential new indications," said Frank Watanabe, president and chief executive officer. "We also continued to generate positive cash flow, underscoring our focus on financial and operational discipline as we continue to advance our corporate strategy."
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy ARQT?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on ARQT
Wall Street analysts forecast ARQT stock price to rise
7 Analyst Rating
7 Buy
0 Hold
0 Sell
Strong Buy
Current: 20.660
Low
30.00
Averages
32.00
High
37.00
Current: 20.660
Low
30.00
Averages
32.00
High
37.00
About ARQT
Arcutis Biotherapeutics, Inc. is a commercial-stage medical dermatology company. The Company develops therapies against biologically validated targets and produces a pipeline for a range of inflammatory dermatological conditions. Its portfolio consists of topical and systemic treatments to treat immune-mediated dermatological diseases and conditions. Its product portfolio includes ZORYVE Roflumilast Cream, ZORYVE Roflumilast Foam, and ARQ-234. The ZORYVE Roflumilast Cream is used for the treatment of seborrheic dermatitis in individuals aged 9 years and older. The ZORYVE Roflumilast Foam for the topical treatment of mild to moderate atopic dermatitis in adults and pediatric patients 6 years of age and older. The ARQ-234 is a fusion protein that is a checkpoint agonist of the CD200 Receptor (CD200R). CD200R is an immune-regulatory receptor which is an immunological checkpoint with a role in the maintenance of immune tolerance.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Arcutis Biotherapeutics Q1 2026 Earnings Call Insights
- Strong Sales Performance: Arcutis reported net product revenues of $105.4 million in Q1 2026, reflecting a 65% increase compared to Q1 2025, indicating robust demand and an enhanced market share in dermatological treatments.
- Increased R&D Spending: R&D expenses rose to $30.6 million from $17.5 million, primarily due to a $10 million milestone obligation linked to the ARQ-234 Phase I trial, showcasing the company's ongoing investment in new product development and confidence in future growth.
- Sales Team Expansion: The company has completed the expansion of its dermatology sales force and initiated the build-out of dedicated primary care and pediatric sales teams, aimed at driving future sales growth and market penetration through enhanced sales capabilities.
- Revenue Guidance Maintained: Despite facing seasonal and weather-related challenges, Arcutis maintains its full-year revenue guidance in the range of $480 million to $495 million, demonstrating management's confidence in market demand and a stable outlook for future performance.
See More
Arcutis Submits ZORYVE Application for Infant Atopic Dermatitis Treatment
- New Drug Application: Arcutis Biotherapeutics has submitted a supplemental New Drug Application seeking to expand the indication for ZORYVE® (roflumilast) cream to treat mild to moderate atopic dermatitis in infants aged 3 months to 24 months, addressing a significant treatment gap in this vulnerable population.
- Clinical Trial Results: The INTEGUMENT-INFANT study demonstrated that ZORYVE cream was well tolerated in 101 infants, with 34.4% achieving treatment success after four weeks, indicating the drug's potential efficacy in this age group.
- Strong Market Demand: Approximately 1 million children under the age of 2 in the U.S. are affected by atopic dermatitis, with only one other FDA-approved topical non-steroidal anti-inflammatory agent available, highlighting the critical need for ZORYVE in the market.
- Strategic Implications: If approved, ZORYVE cream will provide a safe and effective non-steroidal treatment option for infants, helping families reduce steroid use and improve the quality of life for both infants and caregivers.
See More
Arcutis Biotherapeutics Advances ZORYVE in Pediatric Dermatology
- Clinical Trial Results: Arcutis Biotherapeutics presented new Phase 2 data from the INTEGUMENT-INFANT trial at the 2026 American Academy of Dermatology Annual Meeting, showing that 0.05% roflumilast cream was well tolerated in infants aged 3 to 24 months with mild to moderate atopic dermatitis, with about 50% achieving Clear or Almost Clear skin status after 4 weeks of treatment.
- Rapid Relief Effects: A standout finding was that approximately 47% of infants experienced visible improvements in itching within just 10 minutes, significantly impacting the quality of life for infants and their families by addressing a primary distress factor.
- Good Safety Profile: The cream's safety profile remained consistent with previous pediatric trials, demonstrating minimal application site irritation and no serious adverse events, which enhances its potential for use in sensitive populations.
- Future Plans: Based on these positive outcomes, Arcutis plans to submit a supplemental NDA to the FDA in Q2 2026, and if approved, this will expand the ZORYVE portfolio to provide targeted long-term topical treatment options for the most vulnerable pediatric populations.
See More
Biotech IPOs Show Strong Performance in Q1 2026
- Biotech Financing Trends: In Q1 2026, biotech companies raised a median of $287.5 million each, with nearly all possessing mid to late-stage clinical data, indicating a strong market focus on high-value science that boosts investor confidence and capital inflow.
- Industry Focus on High-Value Projects: The IQVIA report reveals that pharmaceutical R&D spending reached $159.1 billion in 2025, with companies redirecting resources toward validated late-stage programs, reflecting a market preference for credible pipelines that enhances the standing of biotech firms.
- Avaí Bio's Major Progress: Avaí Bio is set to present new data on its α-Klotho anti-aging therapy at the Second Annual Klotho Conference, being invited to speak alongside renowned researchers, which signifies an elevation in its influence within the Klotho space and may attract increased investor attention.
- Stoke Therapeutics' Breakthrough Results: Stoke Therapeutics published data on zorevunersen in The New England Journal of Medicine, demonstrating its potential disease-modifying effects in Dravet syndrome, which is expected to propel its Phase 3 EMPEROR study in 2027, further solidifying its market position.
See More
Arcutis Biotherapeutics Executive Sells Shares
- Insider Share Sale: Howard G. Welgus sold 10,000 shares of Arcutis Biotherapeutics on April 1, 2026, for a total value of $239,000, reducing his direct holdings to 39,744 shares, indicating a significantly diminished capacity for future sales.
- Transaction Scale Analysis: This sale of 10,000 shares aligns with the typical monthly trading volume observed since 2023, reflecting a consistent selling pattern from Welgus, and it represents 20% of his direct holdings, highlighting a notable decrease in his ownership stake.
- Company Financial Performance: Arcutis generated $372.1 million in net product revenue in 2025, a 123% increase year-over-year, with fourth-quarter sales reaching $127.5 million, indicating significant progress in its commercialization efforts and improving financial quality.
- Market Outlook: With the successful launch of ZORYVE eczema cream, Arcutis is transitioning from a development phase to a commercial phase, with a regulatory submission planned for 2026, suggesting that long-term investors should focus on the company's accelerating commercialization and expanding indications.
See More
Arcutis Biotherapeutics Director Sells Shares
- Director Share Sale: Howard G. Welgus, a director at Arcutis Biotherapeutics, sold 10,000 shares on April 1, 2026, for a total of $239,000, representing 20.10% of his direct holdings, reducing his stake from 49,744 to 39,744 shares, indicating sustained confidence in the company's future.
- Transaction Context: This sale was executed under a pre-arranged 10b5-1 plan adopted in March 2025, suggesting it was a planned liquidity event rather than a reaction to market fluctuations, especially with the stock up about 65% over the past year.
- Strong Financial Performance: Arcutis generated $372.1 million in net product revenue in 2025, a 123% year-over-year increase, with fourth-quarter sales alone reaching $127.5 million, demonstrating robust momentum in its commercialization efforts and expectations for continued positive operating cash flow.
- Clinical Data Validation: Recent Phase 2 data for ZORYVE cream showed meaningful improvements in infant atopic dermatitis, with rapid itch relief and strong tolerability, supporting a planned regulatory submission in 2026, further solidifying its market position in dermatological treatments.
See More
Arcutis Biotherapeutics Q1 2026 Earnings Call Insights
- Strong Sales Performance: Arcutis reported net product revenues of $105.4 million in Q1 2026, reflecting a 65% increase compared to Q1 2025, indicating robust demand and an enhanced market share in dermatological treatments.
- Increased R&D Spending: R&D expenses rose to $30.6 million from $17.5 million, primarily due to a $10 million milestone obligation linked to the ARQ-234 Phase I trial, showcasing the company's ongoing investment in new product development and confidence in future growth.
- Sales Team Expansion: The company has completed the expansion of its dermatology sales force and initiated the build-out of dedicated primary care and pediatric sales teams, aimed at driving future sales growth and market penetration through enhanced sales capabilities.
- Revenue Guidance Maintained: Despite facing seasonal and weather-related challenges, Arcutis maintains its full-year revenue guidance in the range of $480 million to $495 million, demonstrating management's confidence in market demand and a stable outlook for future performance.
See More
Arcutis Submits ZORYVE Application for Infant Atopic Dermatitis Treatment
- New Drug Application: Arcutis Biotherapeutics has submitted a supplemental New Drug Application seeking to expand the indication for ZORYVE® (roflumilast) cream to treat mild to moderate atopic dermatitis in infants aged 3 months to 24 months, addressing a significant treatment gap in this vulnerable population.
- Clinical Trial Results: The INTEGUMENT-INFANT study demonstrated that ZORYVE cream was well tolerated in 101 infants, with 34.4% achieving treatment success after four weeks, indicating the drug's potential efficacy in this age group.
- Strong Market Demand: Approximately 1 million children under the age of 2 in the U.S. are affected by atopic dermatitis, with only one other FDA-approved topical non-steroidal anti-inflammatory agent available, highlighting the critical need for ZORYVE in the market.
- Strategic Implications: If approved, ZORYVE cream will provide a safe and effective non-steroidal treatment option for infants, helping families reduce steroid use and improve the quality of life for both infants and caregivers.
See More
Arcutis Biotherapeutics Advances ZORYVE in Pediatric Dermatology
- Clinical Trial Results: Arcutis Biotherapeutics presented new Phase 2 data from the INTEGUMENT-INFANT trial at the 2026 American Academy of Dermatology Annual Meeting, showing that 0.05% roflumilast cream was well tolerated in infants aged 3 to 24 months with mild to moderate atopic dermatitis, with about 50% achieving Clear or Almost Clear skin status after 4 weeks of treatment.
- Rapid Relief Effects: A standout finding was that approximately 47% of infants experienced visible improvements in itching within just 10 minutes, significantly impacting the quality of life for infants and their families by addressing a primary distress factor.
- Good Safety Profile: The cream's safety profile remained consistent with previous pediatric trials, demonstrating minimal application site irritation and no serious adverse events, which enhances its potential for use in sensitive populations.
- Future Plans: Based on these positive outcomes, Arcutis plans to submit a supplemental NDA to the FDA in Q2 2026, and if approved, this will expand the ZORYVE portfolio to provide targeted long-term topical treatment options for the most vulnerable pediatric populations.
See More
Biotech IPOs Show Strong Performance in Q1 2026
- Biotech Financing Trends: In Q1 2026, biotech companies raised a median of $287.5 million each, with nearly all possessing mid to late-stage clinical data, indicating a strong market focus on high-value science that boosts investor confidence and capital inflow.
- Industry Focus on High-Value Projects: The IQVIA report reveals that pharmaceutical R&D spending reached $159.1 billion in 2025, with companies redirecting resources toward validated late-stage programs, reflecting a market preference for credible pipelines that enhances the standing of biotech firms.
- Avaí Bio's Major Progress: Avaí Bio is set to present new data on its α-Klotho anti-aging therapy at the Second Annual Klotho Conference, being invited to speak alongside renowned researchers, which signifies an elevation in its influence within the Klotho space and may attract increased investor attention.
- Stoke Therapeutics' Breakthrough Results: Stoke Therapeutics published data on zorevunersen in The New England Journal of Medicine, demonstrating its potential disease-modifying effects in Dravet syndrome, which is expected to propel its Phase 3 EMPEROR study in 2027, further solidifying its market position.
See More
Arcutis Biotherapeutics Executive Sells Shares
- Insider Share Sale: Howard G. Welgus sold 10,000 shares of Arcutis Biotherapeutics on April 1, 2026, for a total value of $239,000, reducing his direct holdings to 39,744 shares, indicating a significantly diminished capacity for future sales.
- Transaction Scale Analysis: This sale of 10,000 shares aligns with the typical monthly trading volume observed since 2023, reflecting a consistent selling pattern from Welgus, and it represents 20% of his direct holdings, highlighting a notable decrease in his ownership stake.
- Company Financial Performance: Arcutis generated $372.1 million in net product revenue in 2025, a 123% increase year-over-year, with fourth-quarter sales reaching $127.5 million, indicating significant progress in its commercialization efforts and improving financial quality.
- Market Outlook: With the successful launch of ZORYVE eczema cream, Arcutis is transitioning from a development phase to a commercial phase, with a regulatory submission planned for 2026, suggesting that long-term investors should focus on the company's accelerating commercialization and expanding indications.
See More
Arcutis Biotherapeutics Director Sells Shares
- Director Share Sale: Howard G. Welgus, a director at Arcutis Biotherapeutics, sold 10,000 shares on April 1, 2026, for a total of $239,000, representing 20.10% of his direct holdings, reducing his stake from 49,744 to 39,744 shares, indicating sustained confidence in the company's future.
- Transaction Context: This sale was executed under a pre-arranged 10b5-1 plan adopted in March 2025, suggesting it was a planned liquidity event rather than a reaction to market fluctuations, especially with the stock up about 65% over the past year.
- Strong Financial Performance: Arcutis generated $372.1 million in net product revenue in 2025, a 123% year-over-year increase, with fourth-quarter sales alone reaching $127.5 million, demonstrating robust momentum in its commercialization efforts and expectations for continued positive operating cash flow.
- Clinical Data Validation: Recent Phase 2 data for ZORYVE cream showed meaningful improvements in infant atopic dermatitis, with rapid itch relief and strong tolerability, supporting a planned regulatory submission in 2026, further solidifying its market position in dermatological treatments.
See More
